Notably, despite this consideration, in our cohort the AF patients did not exhibit a significantly greater deterioration in kidney function over time, possibly due to the optimized GDMT, including the use of RAASis and mineralocorticoid receptor antagonists, which have been shown to confer renal and metabolic protective effects in HFrEF [35]. This evidence concerns the gene NR3C2 and atrial fibrillation.